Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

Poster Session

Hematologic and Oncologic Associated Rheumatic Syndromes

Poster Session B

Session: (1088–1122) Immunological Complications of Medical Therapy Poster

1116: Second-line Therapy for Immune-checkpoint Inhibitor-induced Pneumonitis

Monday, October 27, 2025
10:30 AM - 12:30 PM Central Time
Location: Hall F1
Figure 1. Progression-free survival in refractory or recurrent ICI-pneumonitis patients who received tocilizumab (toci=1, red line) compared to patients who did not receive tocilizumab (toci=0, blue line).

    Abstract Poster Presenter(s)

  • SS

    Sarah Sun, MD, PhD

    Stanford University
    Palo Alto, California, United States

    Disclosure(s): No financial relationships with ineligible companies to disclose


Background/Purpose: Immune checkpoint inhibitors (ICIs) used for cancer therapy can have varied toxicities among which pneumonitis (ICI-pneumonitis) is a rare (< 5%) but often fatal complication. There is scant data to guide second-line therapy for ICI-pneumonitis if systemic steroids are insufficient. We sought to evaluate and compare the effectiveness of key second-line immunosuppressive agents in achieving ICI-pneumonitis resolution.

Methods: For this retrospective observational study, we identified patients with ICI-pneumonitis whose symptoms were refractory or recurrent after systemic steroid treatment and who received a second line agent. We collected data regarding cancer type, ICI type, pneumonitis phenotype and grade, pulmonary comorbidities, steroid details, secondary immunosuppression and outcomes including time to pneumonitis resolution, overall survival, and progression free survival. Count data, t-tests, and chi-square tests were used when appropriate. Cox proportional hazards regression was used for survival data.

Results: Of 1156 patients with ICI-pneumonitis, 13 ICI-pneumonitis patients with second-line treatment (mean age 60.5 (SD 16.5), 8 (61.5%) males) were included in the study. 6 (46.1%) were previous or current smokers, and 9 (69.2%) had pulmonary involvement of their malignancy. 8 (61.5%) patients received chest radiation. All patients had received anti-PD1 monotherapy. Second line immunosuppressive agents included tocilizumab (6 patients), infliximab (4 patients), mycophenolate mofetil (MMF) (4 patients), and Intravenous immunoglobulin (IVIg) (2 patients). Among these, 2 were treated with tocilizumab after failing infliximab or IVIG; one received MMF after failing infliximab. Cancer progression occurred in 2 (50%) MMF, 1 (25%) infliximab, 1 (16.7%) tocilizumab, and 0% patients receiving IVIg. Pneumonitis resolution or sustained improvement occurred most frequently with tocilizumab (4 (66.7%)) compared to MMF (1 (25%), IVIg (0%), or infliximab (0%). The hazard of the combined outcome of progression or death was lower in patients receiving tocilizumab compared to those without; however did not reach statistical significance (Figure 1; HR 0.56, 95% CI 0.16-2.01).

Conclusion: This study, while underpowered, demonstrates that tocilizumab is not associated with worse outcomes and may be associated with improved survival in patients with ICI-pneumonitis. Future studies should prospectively investigate this finding in larger cohorts.